China's innovative pharmaceutical company, HENGRUI PHARMA (01276.HK) will raise $9.89 billion in its IPO at a cap offer price of $44.05, IFR quoted sources as saying.
It was previously rumored that, due to strong demand for IPO subscription, HENGRUI PHARMA would close institutional investor subscriptions a day early at 5 PM on Monday (19th). It is reported that institutional investor demand has topped the entire offering size.
(HK stocks quote is delayed for at least 15 mins.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.